<DOC>
	<DOCNO>NCT02717741</DOCNO>
	<brief_summary>Tafetinib oral multitargeted tyrosine kinase inhibitor inhibit Vascular Endothelial Growth Factor Receptor ( VEGFR ) . This phase I trial conduct evaluate pharmacokinetics ( PK ) , safety , preliminary efficacy tafetinib Chinese patient advance solid tumor . The study conduct Cancer Hospital Chinese Academy Medical Sciences .</brief_summary>
	<brief_title>A Study Tafetinib Chinese Patients With Advanced Solid Tumor</brief_title>
	<detailed_description />
	<criteria>Adult patient histologically confirm advanced solid malignancy . ECOG score 01 . 1865 year old . Withdrawal chemotherapy drug 30 day . No nitrosoureas mitomycin C within previous 6 week . Function organs must meet following requirement : Neutrophil count ≥1500/ul ; AST ALT≤1.5 time upper limit normal ( ULN ) ; Total serum bilirubin≤1.5 time ULN ; Hemoglobin≥90g/L ; Platelet≥100000/ul ; The creatinine normal range creatinine clearance rate ≥60ml/min ; Left ventricular ejection fraction ( LVEF ) ≥50 % ; Females childbearing age require practice effective contraceptive measure negative serum urine pregnancy test study . Written inform consent obtain . included history current brain metastasis , clinically significant cardiovascular disease uncontrolled hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>